AI 기반 골다공증 스크리닝 툴 시장 : 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the AI osteoporosis screening tools market size was valued at USD 299.5 million in 2025 and is estimated to grow from USD 356.77 million in 2026 to reach USD 902.02 million by 2031, at a CAGR of 20.38% during the forecast period (2026-2031).

This report is Segmented by Technology (DXA Analysis, CT/X-Ray AI, Ultrasound AI, Other Tools), Deployment Mode (Cloud, Hybrid, On Premises), End User (Hospitals, Specialty Clinics, Imaging Centers, Primary Care, Academic Institutions), Monetization Model (Subscription, Perpetual License, Per-Scan), and Geography (North America, Europe, Asia-Pacific, MEA, South America).

Global AI Osteoporosis Screening Tools Market Trends and Insights

Rising Osteoporosis Prevalence and Undiagnosed Burden

The AI osteoporosis screening tools market draws steady support from the scale of untreated bone disease across both developed and emerging care systems. The International Osteoporosis Foundation stated in 2025 that more than 500 million people live with osteoporosis worldwide, and only 1 in 5 fracture patients receives a diagnosis or appropriate therapy in many high-income settings. The shortfall is not limited to women, because real-world evidence from Rho showed that AI-prompted DXA referrals identified higher rates of true low bone mineral density in older men than conventional referral practice did, which points to a hidden pool of missed cases in the AI osteoporosis screening tools market. This matters because software that works without a clinician first ordering a dedicated bone exam can convert long-standing referral blind spots into routine screening opportunities inside ordinary imaging pathways. Long-range burden projections also remain severe, with Osteoporosis International projecting 397,537 deaths and 14,350,582 disability-adjusted life years among post-menopausal women from low bone mineral density-related fractures by 2050, which supports a long tail of need for prevention-oriented tools.

Expansion of Opportunistic Screening from Existing Imaging Data

The AI osteoporosis screening tools market is also benefiting from a clear shift toward opportunistic screening, where existing scans are reused to detect bone loss without adding new appointments. A 2025 multicenter cohort study reported that deep learning models applied to chest low-dose CT and lumbar CT delivered high diagnostic accuracy for osteoporosis across scanners from multiple manufacturers, which helps buyers trust wider deployment across mixed imaging fleets. Health systems also gain a practical advantage because opportunistic screening uses imaging that is already part of routine care, which lowers patient friction, avoids added radiation from separate exams, and cuts the need for dedicated screening slots. Economic findings strengthen the case, because studies in Germany, the United States, and Japan each concluded that AI-assisted opportunistic screening can be cost-effective in their respective settings. As a result, the AI osteoporosis screening tools market is moving beyond a narrow radiology software category and toward a broader role in population health detection and fracture prevention workflows.

Limited Reimbursement Visibility for AI-Assisted Screening

Reimbursement remains the most persistent commercial barrier in the AI osteoporosis screening tools market because many facilities still cannot match clinical value with a predictable payment path. Most vendors still rely on facility billing arrangements or per-read economics that are not standardized across payers, which makes revenue planning difficult for providers that want to deploy these tools at scale. The Bone Health and Osteoporosis Foundation stated in its 2024 CMS submission that existing code sets, including changes introduced through the 2025 Physician Fee Schedule, do not capture the coordination costs of fracture prevention and collaborative care programs. Europe faces a similar challenge, because the International Osteoporosis Foundation and Medimaps noted in 2025 that only 1 in 5 fracture patients across the European Union receives diagnosis or therapy, which shows how weak reimbursement and care coordination can limit screening uptake even when clinical need is high. Until payers treat preventive screening and follow-up as a recognized care pathway, the AI osteoporosis screening tools market will continue to face slower rollouts than its technical capabilities might suggest.

Other drivers and restraints analyzed in the detailed report include:

1. AI Automation Reduces Radiologist and Technologist Workload
2. Value-Based Care Incentives for Earlier Risk Stratification
3. Clinician Trust, Explainability, and Liability Concerns

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

AI-Enabled DXA Image Analysis held 47.1% of AI osteoporosis screening tools market share in 2025, which kept it as the largest technology segment because DXA remains the established reference workflow for bone mineral density measurement in clinical practice. Medimaps stated in January 2025 that TBS Osteo Advanced is the only approved medical device software for bone microarchitecture evaluation in clinical settings, is used in more than 4 million procedures each year, and is referenced by more than 30 international clinical guidelines, which shows why DXA-linked software still anchors commercial revenue in the AI osteoporosis screening tools market. This segment benefits from an existing reimbursement structure around DXA, especially in North America, which makes buyer justification more straightforward than it is for newer opportunistic tools. It also fits cleanly into familiar radiology and metabolic bone disease workflows, so hospitals can add value without redesigning how core bone testing is already performed.

Opportunistic CT and X-Ray AI Screening is projected to be the fastest-expanding part of the AI osteoporosis screening tools market size at a 21.4% CAGR through 2031, because it can monetize imaging capacity that health systems already own. The April 2024 FDA De Novo authorization for Rho created a clear regulatory precedent for opportunistic low bone mineral density assessment from standard X-rays, which reduced one of the biggest adoption barriers for this branch of the AI osteoporosis screening tools industry FDA. A 2026 study in a Taiwanese screening population reported an AUC of 0.95 for an AI model reading chest X-rays for abnormal bone mineral density, which supports the clinical case for wider population deployment when local validation is in place. Ultrasound-based AI screening remains relevant in portable and resource-limited settings, while other tools such as combined bone-muscle frailty approaches and AI-assisted fracture risk calculators are still earlier-stage contributors. In rural China, portable DXA programs are already being used to widen screening access, and AI interpretation layers are being added to help scale analysis where specialist infrastructure is limited.

Cloud-based deployment held 56.3% revenue share in 2025 and is also expected to post the fastest growth at 22.3% CAGR through 2031, which makes it the most commercially favored deployment model in the AI osteoporosis screening tools market. This lead reflects the practical needs of AI software, because vendors must manage updates, support multiple sites, and connect outputs back into clinical systems without asking each hospital to maintain a separate software stack. Rho uses FHIR-standard integration to pull relevant data from electronic health records and return findings into workflow, which illustrates why cloud delivery is becoming central for facilities that want the AI osteoporosis screening tools market to operate as part of routine care rather than as a stand-alone application. Medimaps also expanded the case for cloud-style central management in 2025 when it launched TBS Osteo Advanced with multi-site fleet management capabilities, showing how network-level standardization matters in larger health systems.

The cloud segment is also benefiting because it fits the way enterprise buyers now assess software, where ongoing model refinement and shared governance matter as much as the first installation. For multi-location imaging groups, centralized administration reduces the burden of local version control and keeps quality more consistent across sites. That matters in the AI osteoporosis screening tools market because detection accuracy, workflow timing, and clinician acceptance all depend on dependable deployment rather than on algorithm performance alone. Cloud delivery therefore supports the shift from pilot projects toward system-wide contracts.

Complete Report Scope:

• By Technology
  • AI-Enabled DXA Image Analysis
  • Opportunistic CT and X-Ray AI Screening
  • Ultrasound-Based AI Screening
  • Other AI Screening Tools
• By Deployment Mode
  • Cloud Based
  • Hybrid
  • On Premises
• By End User
  • Hospitals and Diagnostic Centers
  • Specialty Orthopedic and Endocrine Clinics
  • Imaging Centers
  • Primary Care Networks
  • Research and Academic Institutions
  • By Monetization Model (Value)
• By Monetization Model (Value)
  • Subscription
  • Perpetual License
  • Per-Scan and Usage Based
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 45.1% of AI osteoporosis screening tools market share in 2025, which made it the largest regional contributor because it combines dense DXA infrastructure, a mature FDA software pathway, and stronger reimbursement foundations than most other regions. The U.S. now adds a sharper demand trigger through TEAM, because hospitals covered under episode-based accountability have a clearer reason to improve bone health detection before costly complications occur. The region also benefits from an active regulatory pipeline, with several vendors already using FDA clearance as a credibility signal when approaching broader provider networks. Canada adds meaningful real-world validation, because routine-care Rho deployments there processed more than 50,000 patients and showed that AI-supported referral pathways can surface under-screened high-risk groups.

Europe remains important for the AI osteoporosis screening tools market because disease burden is large, but commercialization still moves through structural limits in reimbursement and care coordination. The International Osteoporosis Foundation estimated that 32 million Europeans aged 50 and over have osteoporosis, and annual osteoporotic fractures across the European Union, Switzerland, and the UK are projected to reach 5.34 million by 2034. Germany stands out because local research found AI chest radiograph screening to be cost-effective, which gives the region a more practical economic case for broader opportunistic deployment. At the same time, the European route still depends heavily on MDR compliance, and Medimaps' dual U.S. and EU clearance path has become an important reference point for suppliers that want to sell across both regions.

Asia Pacific is set to post the fastest growth in the AI osteoporosis screening tools market size at 22.1% CAGR through 2031, driven by a large aging population, limited DXA access in many countries, and growing acceptance of AI as a practical screening extension. The 2025 APCO-IOFregional audit found that osteoporosis is a national health priority in only 6 audited Asia Pacific countries, which underscores how much unmet need remains across the region. Japan stands out because local research found AI-assisted opportunistic chest radiograph screening to be cost-effective for fracture prevention in older women, even though screening rates remain low. China also represents a strong access-driven opportunity, because portable DXA programs in rural areas are widening screening coverage and creating demand for AI interpretation layers that can compensate for limited specialist capacity. The Middle East and Africa and South America remain early-stage markets, where infrastructure gaps and limited reimbursement still slow adoption, even though later-period digital health investment should create selective openings for the AI osteoporosis screening tools market.

1. Hologic
2. GE Healthcare
3. Siemens Healthineers
4. Koninklijke Philips
5. FUJIFILM
6. Canon
7. Mindray
8. Esaote S.p.A.
9. Carestream Health
10. Agfa-Gevaert
11. Naitive Technologies, Inc.
12. 16 Bit Inc.
13. Qure.AI Technologies Pvt. Ltd.
14. Zebra Medical Vision Ltd.
15. Nanox.AI
16. Gleamer
17. Shukun Technology Co., Ltd.
18. INFERVISION TECHNOLOGY CO., LTD.
19. Medimaps Group SA
20. OSTEOSYS Co., Ltd.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Osteoporosis Prevalence and Undiagnosed Fracture Risk
  • 4.2.2 Expansion of Opportunistic Screening from Routine Imaging Workflows
  • 4.2.3 AI Automation Reduces Radiologist and Technologist Workload
  • 4.2.4 Value-Based Care Incentives for Earlier Risk Stratification
  • 4.2.5 Cloud and EHR Integrated Deployment Improves Scale-Up Speed
  • 4.2.6 Under-Screened Primary Care Populations Create New Catchment Areas
• 4.3 Market Restraints
  • 4.3.1 Regulatory Clearance Burden for Clinical AI in Imaging
  • 4.3.2 Interoperability and Data Governance Constraints
  • 4.3.3 Limited Reimbursement Visibility for AI-Assisted Screening
  • 4.3.4 Clinician Trust, Explainability, and Liability Concerns
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porters Five Forces

5 Market Size & Growth Forecasts

• 5.1 By Technology
  • 5.1.1 AI-Enabled DXA Image Analysis
  • 5.1.2 Opportunistic CT and X-Ray AI Screening
  • 5.1.3 Ultrasound-Based AI Screening
  • 5.1.4 Other AI Screening Tools
• 5.2 By Deployment Mode
  • 5.2.1 Cloud Based
  • 5.2.2 Hybrid
  • 5.2.3 On Premises
• 5.3 By End User
  • 5.3.1 Hospitals and Diagnostic Centers
  • 5.3.2 Specialty Orthopedic and Endocrine Clinics
  • 5.3.3 Imaging Centers
  • 5.3.4 Primary Care Networks
  • 5.3.5 Research and Academic Institutions
• 5.4 By Monetization Model (Value)
  • 5.4.1 Subscription
  • 5.4.2 Perpetual License
  • 5.4.3 Per-Scan and Usage Based
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.4.6 Rest of Europe
  • 5.5.5 Asia-Pacific
    • 5.5.5.1 China
    • 5.5.5.2 India
    • 5.5.5.3 Japan
    • 5.5.5.4 South Korea
    • 5.5.5.5 Australia
    • 5.5.5.6 Rest of Asia-Pacific
  • 5.5.6 Middle East & Africa
    • 5.5.6.1 GCC
    • 5.5.6.2 South Africa
    • 5.5.6.3 Rest of Middle East and Africa
  • 5.5.7 South America
    • 5.5.7.1 Brazil
    • 5.5.7.2 Argentina
    • 5.5.7.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles
  • 6.3.1 Hologic, Inc.
  • 6.3.2 GE HealthCare
  • 6.3.3 Siemens Healthineers AG
  • 6.3.4 Koninklijke Philips N.V.
  • 6.3.5 Fujifilm Holdings Corporation
  • 6.3.6 Canon Medical Systems Corporation
  • 6.3.7 Mindray Medical International Limited
  • 6.3.8 Esaote S.p.A.
  • 6.3.9 Carestream Health, Inc.
  • 6.3.10 Agfa-Gevaert N.V.
  • 6.3.11 Naitive Technologies, Inc.
  • 6.3.12 16 Bit Inc.
  • 6.3.13 Qure.ai Technologies Pvt. Ltd.
  • 6.3.14 Zebra Medical Vision Ltd.
  • 6.3.15 Nanox.AI
  • 6.3.16 Gleamer
  • 6.3.17 Shukun Technology Co., Ltd.
  • 6.3.18 INFERVISION TECHNOLOGY CO., LTD.
  • 6.3.19 Medimaps Group SA
  • 6.3.20 OSTEOSYS Co., Ltd.

7 Market Opportunities & Future Outlook

• 7.1 White Space and Unmet Need Assessment